Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.66), $0.04 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $47 thousand versus the consensus estimate of $60.64 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
• Kroger meets earnings expectations, revenue tops estimates